Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
Shuang Liang,1 Yan-Jun Liang,1 Zhao Li,2 Yong Wang,1 Xin-Ru Guo,1 Chao-yang Zhang,1 Chun Zhang,1 Jie Wu,1 Xiao-Long Wang,1 Yi-Sha Li,1 Guang-Yan Cai,1 Xiang-Mei Chen1 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/evaluating-efficacy-and-safety-of-tacrolimus-treatment-in-membranous-n-peer-reviewed-fulltext-article-TCRM |
| _version_ | 1827967745046609920 |
|---|---|
| author | Liang S Liang YJ Li Z Wang Y Guo XR Zhang CY Zhang C Wu J Wang XL Li YS Cai GY Chen XM |
| author_facet | Liang S Liang YJ Li Z Wang Y Guo XR Zhang CY Zhang C Wu J Wang XL Li YS Cai GY Chen XM |
| author_sort | Liang S |
| collection | DOAJ |
| description | Shuang Liang,1 Yan-Jun Liang,1 Zhao Li,2 Yong Wang,1 Xin-Ru Guo,1 Chao-yang Zhang,1 Chun Zhang,1 Jie Wu,1 Xiao-Long Wang,1 Yi-Sha Li,1 Guang-Yan Cai,1 Xiang-Mei Chen1 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, People’s Republic of China; 2Haikou People’s Hospital Affiliated to Xiangya School of Medicine, Haikou, People’s Republic of ChinaCorrespondence: Guang-Yan Cai, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, People’s Republic of China, Tel +86 13601062936, Fax +86 010-68130297, Email caiguangyan@sina.comPurpose: Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regarding the duration of tacrolimus treatment. Here, we present a real-world retrospective cohort study of 182 MN patients treated with tacrolimus, aiming to assess the efficacy and safety of tacrolimus in the treatment of MN.Patients and Methods: The clinical data of 182 patients with MN treated with tacrolimus and followed up for at least one year were analyzed retrospectively for the efficacy and safety of tacrolimus.Results: The mean follow-up period was 27.3 (19.3– 41.6) months. A total of 154 patients (84.6%) achieved complete or partial remission, and 28 patients (15.4%) did not. Multivariate Cox regression analysis showed that male and higher baseline BMI were independently associated with lower, while higher serum albumin was associated with higher probability of remission. Among the responders, 56 patients (36.4%) relapsed. After adjustments for age and sex, Cox regression analysis revealed that the longer period of full-dose tacrolimus was administered, the lower the incidence of relapse. However, high levels of serum creatinine and proteinuria at the onset of tacrolimus discontinuation were risk factors for relapse. During the treatment of tacrolimus, a decline in renal function (≥ 50% increase in serum creatinine after the onset of tacrolimus treatment) was the most common adverse reaction, observed in 20 (11.0%) patients, followed by elevated blood glucose and infection, but the latter two occurred mostly during treatment with tacrolimus plus corticosteroids.Conclusion: Tacrolimus is effective in the treatment of MN, but the relapse rate is high. Clinical studies with larger sample sizes are needed to further explore the use of tacrolimus in the treatment of membranous nephropathy.Keywords: membranous nephropathy, tacrolimus, response, relapse, safety |
| first_indexed | 2024-04-09T18:10:55Z |
| format | Article |
| id | doaj.art-1a5473a5562f4388bd1e6d42618d2bfb |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-04-09T18:10:55Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-1a5473a5562f4388bd1e6d42618d2bfb2023-04-13T19:17:09ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2023-04-01Volume 1935136082966Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 PatientsLiang SLiang YJLi ZWang YGuo XRZhang CYZhang CWu JWang XLLi YSCai GYChen XMShuang Liang,1 Yan-Jun Liang,1 Zhao Li,2 Yong Wang,1 Xin-Ru Guo,1 Chao-yang Zhang,1 Chun Zhang,1 Jie Wu,1 Xiao-Long Wang,1 Yi-Sha Li,1 Guang-Yan Cai,1 Xiang-Mei Chen1 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, People’s Republic of China; 2Haikou People’s Hospital Affiliated to Xiangya School of Medicine, Haikou, People’s Republic of ChinaCorrespondence: Guang-Yan Cai, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, People’s Republic of China, Tel +86 13601062936, Fax +86 010-68130297, Email caiguangyan@sina.comPurpose: Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regarding the duration of tacrolimus treatment. Here, we present a real-world retrospective cohort study of 182 MN patients treated with tacrolimus, aiming to assess the efficacy and safety of tacrolimus in the treatment of MN.Patients and Methods: The clinical data of 182 patients with MN treated with tacrolimus and followed up for at least one year were analyzed retrospectively for the efficacy and safety of tacrolimus.Results: The mean follow-up period was 27.3 (19.3– 41.6) months. A total of 154 patients (84.6%) achieved complete or partial remission, and 28 patients (15.4%) did not. Multivariate Cox regression analysis showed that male and higher baseline BMI were independently associated with lower, while higher serum albumin was associated with higher probability of remission. Among the responders, 56 patients (36.4%) relapsed. After adjustments for age and sex, Cox regression analysis revealed that the longer period of full-dose tacrolimus was administered, the lower the incidence of relapse. However, high levels of serum creatinine and proteinuria at the onset of tacrolimus discontinuation were risk factors for relapse. During the treatment of tacrolimus, a decline in renal function (≥ 50% increase in serum creatinine after the onset of tacrolimus treatment) was the most common adverse reaction, observed in 20 (11.0%) patients, followed by elevated blood glucose and infection, but the latter two occurred mostly during treatment with tacrolimus plus corticosteroids.Conclusion: Tacrolimus is effective in the treatment of MN, but the relapse rate is high. Clinical studies with larger sample sizes are needed to further explore the use of tacrolimus in the treatment of membranous nephropathy.Keywords: membranous nephropathy, tacrolimus, response, relapse, safetyhttps://www.dovepress.com/evaluating-efficacy-and-safety-of-tacrolimus-treatment-in-membranous-n-peer-reviewed-fulltext-article-TCRMmembranous nephropathytacrolimusresponserelapsesafety |
| spellingShingle | Liang S Liang YJ Li Z Wang Y Guo XR Zhang CY Zhang C Wu J Wang XL Li YS Cai GY Chen XM Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients Therapeutics and Clinical Risk Management membranous nephropathy tacrolimus response relapse safety |
| title | Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients |
| title_full | Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients |
| title_fullStr | Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients |
| title_full_unstemmed | Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients |
| title_short | Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients |
| title_sort | evaluating efficacy and safety of tacrolimus treatment in membranous nephropathy results of a retrospective study of 182 patients |
| topic | membranous nephropathy tacrolimus response relapse safety |
| url | https://www.dovepress.com/evaluating-efficacy-and-safety-of-tacrolimus-treatment-in-membranous-n-peer-reviewed-fulltext-article-TCRM |
| work_keys_str_mv | AT liangs evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT liangyj evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT liz evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT wangy evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT guoxr evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT zhangcy evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT zhangc evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT wuj evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT wangxl evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT liys evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT caigy evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients AT chenxm evaluatingefficacyandsafetyoftacrolimustreatmentinmembranousnephropathyresultsofaretrospectivestudyof182patients |